Insider Buying: GSK (LON:GSK) Insider Buys £108.55 in Stock

Key Points

• Insider purchase: GSK director Julie Brown bought 5 shares on April 13 at GBX 2,171 each (total £108.55) — a very small, symbolic buy that signals personal confidence but is immaterial to float.
• Corporate catalysts: GSK expanded its share buyback (325,000 shares, treasury holdings ~6.36% of voting rights) and reported positive Phase I BEHOLD‑1 results for Mo‑Rez, both of which could support valuation if followed by further progress.
• Market and analyst tone: The stock was up ~0.9% to GBX 2,190 (market cap ~£87.5bn) while broker coverage remains mixed with an average “Hold” rating and an average target of GBX 2,023.57.

GSK plc (LON:GSK - Get Free Report) insider Julie Brown acquired 5 shares of the company's stock in a transaction that occurred on Monday, April 13th. The shares were bought at an average cost of GBX 2,171 per share, for a total transaction of £108.55.

Julie Brown also recently made the following trade(s):

• On Tuesday, February 10th, Julie Brown bought 6 shares of GSK stock. The stock was purchased at an average price of GBX 2,179 per share, with a total value of £130.74.

GSK Stock Up 0.9%

GSK stock traded up GBX 20 during trading hours on Tuesday, reaching GBX 2,190. The stock had a trading volume of 5,034,690 shares, compared to its average volume of 9,384,402. The company has a market cap of £87.53 billion, a price-to-earnings ratio of 15.78, a PEG ratio of 1.24 and a beta of 0.35. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. The business's 50 day moving average price is GBX 2,105.91 and its 200-day moving average price is GBX 1,885.52. GSK plc has a 52 week low of GBX 1,263.50 and a 52 week high of GBX 2,282.

GSK (LON:GSK - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Sell-side analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Analyst Upgrades and Downgrades

GSK has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft increased their price objective on GSK from GBX 1,600 to GBX 1,675 and gave the company a "hold" rating in a report on Thursday, January 15th. UBS Group reissued a "neutral" rating and issued a GBX 1,940 price objective on shares of GSK in a report on Friday, January 23rd. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a report on Wednesday, January 7th. Berenberg Bank reissued a "hold" rating and issued a GBX 2,000 price objective on shares of GSK in a report on Thursday, March 26th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a GBX 2,500 price objective on shares of GSK in a report on Tuesday. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of GBX 2,023.57.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK expanded its share buyback, repurchasing 325,000 ordinary shares and lifting treasury holdings to about 6.36% of voting rights — a direct capital-return move that reduces float and supports EPS. GSK Expands Share Buyback, Lifts Treasury Holdings to 6.36% of Voting Rights
• Positive Sentiment: GSK reported positive Phase I BEHOLD‑1 results for Mo‑Rez (candidate for ovarian and endometrial cancer), which increases the drug’s development and commercial upside if later‑stage trials confirm benefit. This pipeline news can lift long‑term valuation expectations. GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
• Positive Sentiment: Jefferies reaffirmed its “buy” rating on GSK and kept a GBX 2,500 price target — a supportive analyst signal that may attract buyer interest given the gap to the current share price. Broker Views (Jefferies reaffirmation)
• Neutral Sentiment: Several senior executives acquired shares under a company reward plan (routine/expected insider participation). Such transactions are typically neutral-to-modestly positive for sentiment but not large enough to materially move valuation by themselves. GSK Executives Acquire Shares Under Company Reward Plan
• Neutral Sentiment: Insider purchase: Julie Brown bought 5 shares at ~GBX 2,171. The size is immaterial for float but signals management confidence at a personal level. (No article link provided.)
• Negative Sentiment: Aggregate broker coverage remains cautious overall — GSK received an average “Hold” rating from brokerages, which could cap upside if the market looks for broader analyst upgrades beyond isolated buy calls. GSK plc LON: GSK Receives Average Rating of "Hold" from Brokerages

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.